{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:00:18Z","timestamp":1781089218058,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.medcli.2019.11.002","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T21:02:27Z","timestamp":1578517347000},"page":"351-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Nuevos antibi\u00f3ticos para el tratamiento de las infecciones por microorganismos multirresistentes"],"prefix":"10.1016","volume":"154","author":[{"given":"Laura","family":"Escol\u00e0-Verg\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibai","family":"Los-Arcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benito","family":"Almirante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2019.11.002_bib0305","unstructured":"WHO. The burden of health care-associated infection worldwide; 2016 [consultado 6 Ago 2019]. Disponible en: http:\/\/www.who.int\/gpsc\/country_ work\/burden_hcai\/en\/"},{"key":"10.1016\/j.medcli.2019.11.002_bib0310","unstructured":"Antimicrobial resistance surveillance in Europe 2016. European Centre for Disease Prevention and Control [consultado 6 Ago 2019]. Disponible en: https:\/\/ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-surveillance-europe-2016"},{"key":"10.1016\/j.medcli.2019.11.002_bib0315","unstructured":"O\u2019Neill J. Tackling drug-resistant infections globally: final report and recommendations. The Review on Antimicrobial Resistance; mayo 2016 [consultado 6 Ago 2019]. Disponible en: https:\/\/amr-review.org\/sites\/default\/files\/160518_Final%20paper_with%20cover.pdf"},{"key":"10.1016\/j.medcli.2019.11.002_bib0320","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2147\/IDR.S180905","article-title":"Ceftolozane\/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy","volume":"12","author":"Escol\u00e0-Verg\u00e9","year":"2019","journal-title":"Infect Drug Resist."},{"key":"10.1016\/j.medcli.2019.11.002_bib0325","doi-asserted-by":"crossref","first-page":"e00031-19","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev."},{"key":"10.1016\/j.medcli.2019.11.002_bib0330","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs."},{"key":"10.1016\/j.medcli.2019.11.002_bib0335","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s15010-018-1133-5","article-title":"Ceftolozane\/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections","volume":"46","author":"Escol\u00e0-Verg\u00e9","year":"2018","journal-title":"Infection."},{"key":"10.1016\/j.medcli.2019.11.002_bib0340","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fpubh.2019.00151","article-title":"The \u00abOld\u00bb and the \u00abNew\u00bb antibiotics for MDR gram-negative pathogens: for whom, when, and how","volume":"7","author":"Karaiskos","year":"2019","journal-title":"Front Public Health."},{"key":"10.1016\/j.medcli.2019.11.002_bib0345","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","article-title":"Ceftazidime-avibactam: a review in the treatment of serious Gram-negative bacterial infections","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs."},{"key":"10.1016\/j.medcli.2019.11.002_bib0350","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/acsinfecdis.7b00020","article-title":"Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients","volume":"3","author":"Papp-Wallace","year":"2017","journal-title":"ACS Infect Dis."},{"key":"10.1016\/j.medcli.2019.11.002_bib0355","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s15010-018-1261-y","article-title":"Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime-avibactam","volume":"47","author":"Los-Arcos","year":"2019","journal-title":"Infection."},{"issue":"Suppl. 2","key":"10.1016\/j.medcli.2019.11.002_bib0360","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/jac\/dki005","article-title":"Origin, structure, and activity in vitro and in vivo of dalbavancin","volume":"55","author":"Malabarba","year":"2005","journal-title":"J Antimicrob Chemother."},{"issue":"Supl. 1","key":"10.1016\/j.medcli.2019.11.002_bib0365","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0213-005X(17)30029-0","article-title":"Espectro antimicrobiano de dalbavancina Mecanismo de acci\u00f3n y actividad in vitro frente a microorganismos Gram positivos","volume":"35","author":"Cercenado","year":"2017","journal-title":"Enf Infecc Microbiol Clin."},{"key":"10.1016\/j.medcli.2019.11.002_bib0370","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.diagmicrobio.2005.03.004","article-title":"Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens","volume":"53","author":"Streit","year":"2005","journal-title":"Diag Microbiol Infect Dis."},{"key":"10.1016\/j.medcli.2019.11.002_bib0375","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/microorganisms7080270","article-title":"Novel antibiotics for multidrug-resistant Gram-positive microorganisms","volume":"7","author":"Koulenti","year":"2019","journal-title":"Microorganisms."},{"key":"10.1016\/j.medcli.2019.11.002_bib0380","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.medcli.2019.11.002_bib0385","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2019.11.002_bib0390","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2019.11.002_bib0395","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2019.11.002_bib0400","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2019.11.002_bib0405","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2019.11.002_bib0410","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis."},{"key":"10.1016\/j.medcli.2019.11.002_bib0415","doi-asserted-by":"crossref","first-page":"ofz274","DOI":"10.1093\/ofid\/ofz274","article-title":"Long-acting lipoglycopeptides: \u201clineless antibiotics\u201d for serious infections in persons who use drugs","volume":"6","author":"Morrisette","year":"2019","journal-title":"Open Forum Infect Dis."},{"key":"10.1016\/j.medcli.2019.11.002_bib0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-015-0060-3","article-title":"Tedizolid phosphate: a next-generation oxazolidinone","volume":"4","author":"Rybak","year":"2015","journal-title":"Infect Dis Ther."},{"key":"10.1016\/j.medcli.2019.11.002_bib0425","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40265-015-0352-7","article-title":"Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant Gram-positive pathogens","volume":"75","author":"Zhanel","year":"2015","journal-title":"Drugs."},{"key":"10.1016\/j.medcli.2019.11.002_bib0430","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/phar.1491","article-title":"Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance","volume":"34","author":"Rybak","year":"2014","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.medcli.2019.11.002_bib0435","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1093\/jac\/dkz216","article-title":"Efficacy and safety of long-term use of tedizolid after liver transplantation in an adolescent with pulmonary tuberculosis","volume":"74","author":"Yuste","year":"2019","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.medcli.2019.11.002_bib0440","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.03688-14","article-title":"Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections","volume":"59","author":"Shorr","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.medcli.2019.11.002_bib0445","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1586\/eri.12.112","article-title":"Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA","volume":"10","author":"Garrison","year":"2012","journal-title":"Expert Rev Anti Infect Ther."},{"key":"10.1016\/j.medcli.2019.11.002_bib0450","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/00003495-200969070-00003","article-title":"Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus","volume":"69","author":"Zhanel","year":"2009","journal-title":"Drugs."},{"key":"10.1016\/j.medcli.2019.11.002_bib0455","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijantimicag.2017.05.006","article-title":"Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new","volume":"50","author":"David","year":"2017","journal-title":"Int J Antimicrob Agents."},{"issue":"Suppl. 3","key":"10.1016\/j.medcli.2019.11.002_bib0460","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother."},{"issue":"Suppl. 3","key":"10.1016\/j.medcli.2019.11.002_bib0465","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.medcli.2019.11.002_bib0470","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.05738-11","article-title":"CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections","volume":"56","author":"Friedland","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"issue":"Suppl. 4","key":"10.1016\/j.medcli.2019.11.002_bib0475","first-page":"iv53","article-title":"CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.medcli.2019.11.002_bib0480","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1093\/jac\/dkw333","article-title":"A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600mg every 8h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities","volume":"71","author":"Dryden","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.medcli.2019.11.002_bib0485","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/jac\/dkw062","article-title":"High incidence of neutropenia in patients with prolonged ceftaroline exposure","volume":"71","author":"Furtek","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.medcli.2019.11.002_bib0490","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/1120009X.2017.1351729","article-title":"Ceftaroline for the treatment of osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case series","volume":"30","author":"Lalikian","year":"2018","journal-title":"J Chemother."},{"key":"10.1016\/j.medcli.2019.11.002_bib0495","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/jac\/dku085","article-title":"Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study","volume":"69","author":"Tattevin","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.medcli.2019.11.002_bib0500","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijid.2017.01.019","article-title":"Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study","volume":"57","author":"Arshad","year":"2017","journal-title":"Int J Infect Dis."},{"key":"10.1016\/j.medcli.2019.11.002_bib0505","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1128\/AAC.04068-14","article-title":"Missense mutations in PBP2A affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998","volume":"59","author":"Kelley","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.medcli.2019.11.002_bib0510","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1517\/14656560903048967","article-title":"Ceftobiprole: a new broad spectrum cephalosporin","volume":"10","author":"El Solh","year":"2009","journal-title":"Expert Opin Pharmacother."},{"issue":"Suppl. 3","key":"10.1016\/j.medcli.2019.11.002_bib0515","first-page":"3","article-title":"Mechanisms of action and antimicrobial activity of ceftobiprole","volume":"32","author":"Morosini","year":"2019","journal-title":"Rev Esp Quimioter."},{"issue":"Suppl. 2","key":"10.1016\/j.medcli.2019.11.002_bib0520","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-0691.2007.01722.x","article-title":"In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus","volume":"13","author":"Jones","year":"2007","journal-title":"Clin Microbiol Infect."},{"issue":"Suppl. 3","key":"10.1016\/j.medcli.2019.11.002_bib0525","first-page":"11","article-title":"Ceftobiprole: pharmacokinetics and PK\/PD profile","volume":"32","author":"Azanza Perea","year":"2019","journal-title":"Rev Esp Quimioter."},{"key":"10.1016\/j.medcli.2019.11.002_bib0530","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.medcli.2019.11.002_bib0535","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis."},{"issue":"Suppl. 3","key":"10.1016\/j.medcli.2019.11.002_bib0540","first-page":"29","article-title":"Possible clinical indications of ceftobiprole","volume":"32","author":"Barber\u00e1n","year":"2019","journal-title":"Rev Esp Quimioter."},{"key":"10.1016\/j.medcli.2019.11.002_bib0545","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4140\/TCP.n.2019.187","article-title":"A brief review of a new antibiotic: meropenem-vaborbactam","volume":"34","author":"Gibson","year":"2019","journal-title":"Sr Care Pharm."},{"key":"10.1016\/j.medcli.2019.11.002_bib0550","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40265-019-01112-1","article-title":"New drugs for multidrug-resistant Gram-negative organisms: time for stewardship","volume":"79","author":"Jean","year":"2019","journal-title":"Drugs."},{"key":"10.1016\/j.medcli.2019.11.002_bib0555","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14787210.2019.1612240","article-title":"Cefiderocol: a promising antibiotic against multidrug-resistant Gram-negative bacteria","volume":"17","author":"Jean","year":"2019","journal-title":"Expert Rev Anti Infect Ther."},{"key":"10.1016\/j.medcli.2019.11.002_bib0560","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2147\/IDR.S202160","article-title":"Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Lan","year":"2019","journal-title":"Infect Drug Resist."},{"key":"10.1016\/j.medcli.2019.11.002_bib0565","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jmii.2017.07.011","article-title":"Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial","volume":"52","author":"Yuan","year":"2019","journal-title":"J Microbiol Immunol Infect."},{"key":"10.1016\/j.medcli.2019.11.002_bib0570","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1517\/14656566.2015.978288","article-title":"The potential role of nemonoxacin for treatment of common infections","volume":"16","author":"Huang","year":"2015","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.medcli.2019.11.002_bib0575","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1080\/14656566.2019.1617851","article-title":"Novel developments in the treatment of acute bacterial skin and skin structure infections","volume":"20","author":"Jaffa","year":"2019","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.medcli.2019.11.002_bib0580","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.2147\/IDR.S171352","article-title":"Omadacycline:a novel aminomethylcycline","volume":"12","author":"Burgos","year":"2019","journal-title":"Infect Drug Resist."},{"key":"10.1016\/j.medcli.2019.11.002_bib0585","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3390\/jcm8060866","article-title":"The efficacy and safety of eravacycline in the treatment of complicated intra-abdominal infections: a systemic review and meta-analysis of randomized controlled trials","volume":"8","author":"Lan","year":"2019","journal-title":"J Clin Med."},{"key":"10.1016\/j.medcli.2019.11.002_bib0590","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz640","article-title":"Plazomicin: a new aminoglycoside","author":"Saravolatz","year":"2019","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2019.11.002_bib0595","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41429-017-0017-8","article-title":"Kanamycin and its derivative, arbekacin: significance and impact","volume":"71","author":"Hotta","year":"2018","journal-title":"J Antibiot."},{"key":"10.1016\/j.medcli.2019.11.002_bib0600","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/phar.2166","article-title":"Lefamulin: review of a promising novel pleuromutilin antibiotic","volume":"38","author":"Veve","year":"2018","journal-title":"Pharmacotherapy."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319307110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319307110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T11:43:16Z","timestamp":1665402196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775319307110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0025775319307110"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2019.11.002","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nuevos antibi\u00f3ticos para el tratamiento de las infecciones por microorganismos multirresistentes","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2019.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}